Mustang Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2018

The following table summarizes stock option activities for the three months ended March 31, 2018:

	Stock Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)
Nonvested at December 31, 2017		1,241,675	$	5.73		9.31
Options granted		-	$	-		-
Options outstanding		1,241,675	$	5.73		9.06
Options vested and exercisable at March 31, 2018	$	-	$	-	$	-

The following table summarizes stock-based compensation expense for the three months ended March 31, 2018 (in thousands).

	For the three months ended March 31,
	2018
Employee	$	705
Non-employee		1,290
Total stock-based compensation expense	$	1,995

A summary of warrant activities for three months ended March 31, 2018 is presented below:

	Warrants		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)
Outstanding as of December 31, 2017		5,253,318	$	8.28		3.89
Granted		-		-		-
Exercised		(30,543)		3.15		-
Outstanding as of March 31, 2018		5,222,775	$	8.31		3.85

The following table summarizes restricted stock award activities for the three months ended March 31, 2018:

	Number of Shares		Weighted Average Grant Date Fair Value
Nonvested at December 31, 2017		180,000	$	5.73
Granted		-		-
Nonvested at March 31, 2018		180,000	$	5.73

The following table summarizes restricted stock units activities for the three months ended March 31, 2018:

	Number of Units		Weighted Average Grant Date Fair Value
Nonvested at December 31, 2017		134,000	$	6.53
Granted		275,000		10.55
Vested		(100,000)		10.29
Nonvested at March 31, 2018		309,000	$	8.89